FATE - Fate Therapeutics, Inc.
| Previous Close | 13.50 |
| Open | 13.61 |
| Bid | 14.47 x 1100 |
| Ask | 14.47 x 900 |
| Day's Range | 13.43 - 14.53 |
| 52 Week Range | 3.80 - 16.94 |
| Volume | 381,287 |
| Avg. Volume | 587,443 |
| Market Cap | 908.392M |
| Beta (3Y Monthly) | 2.56 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.19 |
| Earnings Date | Oct 30, 2018 - Nov 5, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.67 |
- GlobeNewswire•12 days ago
Fate Therapeutics Appoints Wen Bo Wang, Ph.D. as Senior Vice President, Technical Operations
Fate Therapeutics, Inc. (FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Wen Bo Wang, Ph.D., a leading expert in the manufacture of pluripotent stem cell-derived cell products, has joined the Company as Senior Vice President, Technical Operations. Dr. Wang brings to Fate Therapeutics more than 18 years of cell therapy leadership, having most recently served as Senior Vice President, Cell Therapy Research & Development at FUJIFILM Cellular Dynamics, Inc. Dr. Wang will be responsible for shaping the Company’s manufacturing strategies for its pipeline of off-the-shelf cell-based cancer immunotherapy candidates and scaling the Company’s induced pluripotent stem cell (iPSC) product platform to support late-stage clinical and commercial operations.
- Barrons.com•13 days ago
This Biotech Stock Has Quadrupled — and Its Top Shareholder Is Still Buying
Fate Therapeutics has quadrupled in the past 12 months and has more than doubled this year. Top shareholder Redmile Group still wanted to buy more.
- GlobeNewswire•21 days ago
Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the closing of an underwritten public offering of 10,648,149 shares of its common stock, which included 1,388,889 shares that were issued pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $13.50 per share. Fate Therapeutics intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies, the manufacture of clinical product candidates and the conduct of preclinical research and development, and for general corporate purposes. Jefferies, Piper Jaffray, and Wells Fargo Securities acted as joint book-running managers for the offering.
- GlobeNewswire•21 days ago
Fate Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Sept. 25, 2018-- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced ...
- GlobeNewswire•26 days ago
Fate Therapeutics Announces Pricing of Public Offering of Common Stock
Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the pricing of an underwritten public offering of 9,259,260 shares of its common stock at a public offering price of $13.50 per share, before underwriting discounts, for an aggregate offering of approximately $125.0 million. Fate Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,388,889 shares of its common stock. The proceeds to Fate Therapeutics from this offering are expected to be approximately $117.2 million after deducting underwriting discounts and commissions and other estimated offering expenses but excluding any exercise of the underwriters’ option.
- GlobeNewswire•26 days ago
Fate Therapeutics Announces Proposed Public Offering of Common Stock
Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has commenced an underwritten public offering of its common stock. Fate Therapeutics intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies, the manufacture of clinical product candidates and the conduct of preclinical research and development, and for general corporate purposes. All shares of common stock to be sold in the offering will be offered by Fate Therapeutics.
- Simply Wall St.•26 days ago
Why You Need To Look At This Factor Before Buying Fate Therapeutics Inc (NASDAQ:FATE)
If you own shares in Fate Therapeutics Inc (NASDAQ:FATE) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measureRead More...
- GlobeNewswire•29 days ago
Fate Therapeutics Announces Strategic Collaboration with ONO Pharmaceutical to Develop Off-the-Shelf, iPSC-derived CAR-T Cell Cancer Immunotherapies
Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it has entered into a collaboration with ONO Pharmaceutical Co., Ltd. for the joint development and commercialization of two off-the-shelf CAR-T cell product candidates. Using Fate Therapeutics’ proprietary induced pluripotent stem cell (iPSC) product platform, the two CAR T-cell collaboration candidates will each be derived from a clonal master iPSC line engineered to completely eliminate endogenous TCR expression, insert a chimeric antigen receptor (CAR) into the TRAC locus and incorporate other anti-tumor functionality.
- GlobeNewswire•last month
Fate Therapeutics Enters into Exclusive License Agreement with Gladstone Institutes for CRISPR-based Cellular Reprogramming
Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today the Company has exclusively licensed intellectual property from the J. David Gladstone Institutes that covers the generation of induced pluripotent stem cells (iPSCs) using CRISPR-mediated gene activation. This new approach for inducing pluripotency uses CRISPR to directly target a specific location of the genome and activate endogenous gene expression, and does not rely on established methods of cellular reprogramming that require the transduction of multiple transcription factors. The discovery was made by a team of scientists led by Sheng Ding, Ph.D., a senior investigator at Gladstone and a scientific founder of Fate Therapeutics.
- Thomson Reuters StreetEvents•last month
Edited Transcript of FATE earnings conference call or presentation 6-Aug-18 9:00pm GMT
Q2 2018 Fate Therapeutics Inc Earnings Call
- GlobeNewswire•2 months ago
Research Report Identifies Kronos Worldwide, The Gap, Citigroup, Cadence Design, SPX FLOW, and Fate Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Aug. 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Kronos ...
- GlobeNewswire•2 months ago
Fate Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Aug. 29, 2018-- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced ...
- GlobeNewswire•2 months ago
Fate Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference
SAN DIEGO, Aug. 07, 2018-- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced ...
- Zacks•2 months ago
Fate Therapeutics (FATE) Reports Q2 Loss, Lags Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -32.14% and -19.26%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Fate Therapeutics: 2Q Earnings Snapshot
The San Diego-based company said it had a loss of 37 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a ...
- GlobeNewswire•2 months ago
Fate Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Operational Progress
Treated 20 th Subject in Phase 2 PROTECT Study of ProTmune. Opened Second Site for Enrollment of FATE-NK100 DIMENSION Study. Submitted First-of-Kind IND to FDA for Universal Off-the-Shelf NK Cell Product ...
- ACCESSWIRE•2 months ago
Fate Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Fate Therapeutics, Inc. (NASDAQ: FATE ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 5:00 PM Eastern ...
- Benzinga•2 months ago
Fate Therapeutics Q2 Earnings Preview
Fate Therapeutics (NASDAQ: FATE ) releases its next round of earnings Monday. Here's Benzinga's essential guide to Fate Therapeutics' Q2 earnings report. Earnings and Revenue Analysts are expecting Fate ...
- GlobeNewswire•3 months ago
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2018 Financial Results
SAN DIEGO, July 30, 2018-- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced ...
- GlobeNewswire•3 months ago
Recent Analysis Shows Synopsys, Rigel Pharmaceuticals, Fate Therapeutics, Philip Morris International, Sally Beauty, and Kimberly-Clark Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, July 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Synopsys, ...
- GlobeNewswire•3 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Board of Directors of Fate Therapeutics, Inc. -- FATE
NEW YORK, July 26, 2018-- Levi & Korsinsky announces it has commenced an investigation of Fate Therapeutics, Inc. concerning possible breaches of fiduciary duty. To obtain additional information, go to:. ...
- PR Newswire•3 months ago
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Fate Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK , July 26, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...
- ACCESSWIRE•3 months ago
Free Pre-Market Technical Pulse on FibroGen and Three More Biotech Stocks
LONDON, UK / ACCESSWIRE / July 10, 2018 / If you want a free Stock Review on FGEN sign up now at www.wallstequities.com/registration. Pre-market, WallStEquities.com evaluates EyeGate Pharmaceuticals Inc. (NASDAQ: EYEG), EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT), Fate Therapeutics Inc. (NASDAQ: FATE), and FibroGen Inc. (NASDAQ: FGEN).
- Investopedia•4 months ago
3 Sectors to Buy in a Trade War
A full-blown trade war could test the resiliency of the nine-year bull market, with key groups exposed to a major correction, but a handful of sectors could thrive in the challenging conditions and find their way to new highs.
- Market Realist•4 months ago
TransEnterix Stock Rose 5.6% on Friday and Early on June 4
TransEnterix (TRXC) is a US-based medical device company that focuses on digitizing the interfaces between the surgeon and the patient. The stock price increased ~5.6% and closed at $3.75 on June 1. On May 31, TransEnterix announced that Louisiana State University Health New Orleans School of Medicine purchased the Senhance Surgical System, which was developed by TransEnterix.
